171 related articles for article (PubMed ID: 38554489)
1. Exploiting the immune system in hepatic tumor targeting: Unleashing the potential of drugs, natural products, and nanoparticles.
Hsu CY; Mustafa MA; Kumar A; Pramanik A; Sharma R; Mohammed F; Jawad IA; Mohammed IJ; Alshahrani MY; Ali Khalil NAM; Shnishil AT; Abosaoda MK
Pathol Res Pract; 2024 Apr; 256():155266. PubMed ID: 38554489
[TBL] [Abstract][Full Text] [Related]
2. Targeting anticancer immunity in oral cancer: Drugs, products, and nanoparticles.
Qin L; Wu J
Environ Res; 2023 Dec; 239(Pt 1):116751. PubMed ID: 37507044
[TBL] [Abstract][Full Text] [Related]
3. Tumor-associated Macrophages (TAMs) in Cancer Resistance; Modulation by Natural Products.
Lafta HA; AbdulHussein AH; Al-Shalah SAJ; Alnassar YS; Mohammed NM; Akram SM; Qasim MT; Najafi M
Curr Top Med Chem; 2023; 23(12):1104-1122. PubMed ID: 36722486
[TBL] [Abstract][Full Text] [Related]
4. Charge-switchable nanoparticles enhance Cancer immunotherapy based on mitochondrial dynamic regulation and immunogenic cell death induction.
Zhao M; Li J; Liu J; Xu M; Ji H; Wu S; Chen D; Hu H
J Control Release; 2021 Jul; 335():320-332. PubMed ID: 34062192
[TBL] [Abstract][Full Text] [Related]
5. Delicaflavone reactivates anti-tumor immune responses by abrogating monocytic myeloid cell-mediated immunosuppression.
Li L; You W; Wang X; Zou Y; Yao H; Lan H; Lin X; Zhang Q; Chen B
Phytomedicine; 2023 Jan; 108():154508. PubMed ID: 36332384
[TBL] [Abstract][Full Text] [Related]
6. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
7. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
8. The exploitation of enzyme-based cancer immunotherapy.
Chandan G; Saini AK; Kumari R; Chakrabarti S; Mittal A; Sharma AK; Saini RV
Hum Cell; 2023 Jan; 36(1):98-120. PubMed ID: 36334180
[TBL] [Abstract][Full Text] [Related]
9. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
Gaggero S; Witt K; Carlsten M; Mitra S
Front Immunol; 2020; 11():621225. PubMed ID: 33584718
[TBL] [Abstract][Full Text] [Related]
10. Targeting of the tumor immune microenvironment by metformin.
Wu Z; Zhang C; Najafi M
J Cell Commun Signal; 2022 Sep; 16(3):333-348. PubMed ID: 34611852
[TBL] [Abstract][Full Text] [Related]
11. Modulating the tumor immune microenvironment with nanoparticles: A sword for improving the efficiency of ovarian cancer immunotherapy.
Xu T; Liu Z; Huang L; Jing J; Liu X
Front Immunol; 2022; 13():1057850. PubMed ID: 36532066
[TBL] [Abstract][Full Text] [Related]
12. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
[TBL] [Abstract][Full Text] [Related]
13. T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems.
Yang YL; Yang F; Huang ZQ; Li YY; Shi HY; Sun Q; Ma Y; Wang Y; Zhang Y; Yang S; Zhao GR; Xu FH
Front Immunol; 2023; 14():1199173. PubMed ID: 37457707
[TBL] [Abstract][Full Text] [Related]
14. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
15. Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies.
Ngiow SF; Young A
Front Immunol; 2020; 11():1633. PubMed ID: 32849557
[TBL] [Abstract][Full Text] [Related]
16. Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy.
Peng P; Lou Y; Wang S; Wang J; Zhang Z; Du P; Zheng J; Liu P; Xu LX
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36521929
[TBL] [Abstract][Full Text] [Related]
17. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
[TBL] [Abstract][Full Text] [Related]
18. Targeting the immune microenvironment for ovarian cancer therapy.
Blanc-Durand F; Clemence Wei Xian L; Tan DSP
Front Immunol; 2023; 14():1328651. PubMed ID: 38164130
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
Carnevalli LS; Ghadially H; Barry ST
Front Immunol; 2021; 12():633685. PubMed ID: 33953710
[TBL] [Abstract][Full Text] [Related]
20. Emerging role of natural products in cancer immunotherapy.
Dong S; Guo X; Han F; He Z; Wang Y
Acta Pharm Sin B; 2022 Mar; 12(3):1163-1185. PubMed ID: 35530162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
